114 related articles for article (PubMed ID: 8054701)
1. Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Kinder DH; Berger MS; Mueller BA; Silber JR
Oncol Res; 1993; 5(10-11):409-14. PubMed ID: 8054701
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
3. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
4. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
5. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
6. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Landau BJ; Kwaan HC; Verrusio EN; Brem SS
Cancer Res; 1994 Feb; 54(4):1105-8. PubMed ID: 8313368
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Caccamo DV; Keohane ME; McKeever PE
Mod Pathol; 1994 Jan; 7(1):99-104. PubMed ID: 8159659
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
11. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
12. The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
Herszényi L; Plebani M; Cardin R; Carraro P; De Paoli M; Roveroni G; Naccarato R; Farinati F
Acta Physiol Hung; 1995; 83(3):213-21. PubMed ID: 8852646
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
15. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
16. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
17. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of urokinase-type plasminogen activator in human gliomas.
Hsu DW; Efird JT; Hedley-Whyte ET
Am J Pathol; 1995 Jul; 147(1):114-23. PubMed ID: 7604873
[TBL] [Abstract][Full Text] [Related]
20. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]